Penn physician and historian Robert Aronowitz elected to Institute of Medicine

October 20, 2014

Robert Aronowitz, a physician and historian at the University of Pennsylvania, has been elected to membership in the Institute of Medicine, one of the nation's highest honors in the health-care field. He joins 69 other new members and 10 foreign associates in the 2014 class.

The newly elected members raise IOM's total active membership to 1,798 and the number of foreign associates to 128.

Established in 1970 by the National Academy of Sciences, IOM has become recognized as a national resource for independent, scientifically informed analysis and recommendations on health issues. With their election, members make a commitment to volunteer their service on IOM committees, boards and other activities.

Aronowitz is chair of the Department of History and Sociology of Science in Penn's School of Arts & Sciences. He also holds an appointment in Penn's Perelman School of Medicine.

Part of the IOM's mission is to recognize professionals not only in medicine but in the social sciences and humanities. Aronowitz's career has encompassed a broad range of disciplines, from English literature and linguistics to medicine and history. After receiving a master's from Columbia Teachers College, he began another degree in linguistics at the University of California, Berkeley, before pursuing his M.D. at Yale University. He completed residency training in internal medicine at Pennsylvania Hospital, part of the University of Pennsylvania Health System, and went on to receive training in the history of medicine as a Robert Wood Johnson Foundation Clinical Scholar at Penn.

Aronowitz's research interests revolve around the history of medicine and epidemiology and the role that risk and efficacy have played in driving trends and outcomes in health care. His award-winning book, Unnatural History: Breast Cancer and American Society, for example, illuminates how breast cancer is viewed, diagnosed and treated today through the lens of the past 200 years. Other writings have investigated the politics of the HPV vaccine, how diseases become "legitimized" and the social construction of Lyme disease. An article published last year, "From Skid Row to Main Street: The Bowery Series and the Transformation of Prostate Cancer, 1951-1966," received attention from The New York Times and helped spark a national dialogue about prostate cancer screening.

A new book, Risky Medicine: How Identifying and Treating Risk Is Transforming Our Health and Health Care, will appear in the spring, published by the University of Chicago Press.

Earlier this year, Aronowitz was honored with the Jacob Ehrenzeller Award, given to former residents of Pennsylvania Hospital who have excelled in their fields.
-end-


University of Pennsylvania

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.